WO2017168444A1 - An improved process for the preparation of butorphanol tartrate - Google Patents
An improved process for the preparation of butorphanol tartrate Download PDFInfo
- Publication number
- WO2017168444A1 WO2017168444A1 PCT/IN2017/050112 IN2017050112W WO2017168444A1 WO 2017168444 A1 WO2017168444 A1 WO 2017168444A1 IN 2017050112 W IN2017050112 W IN 2017050112W WO 2017168444 A1 WO2017168444 A1 WO 2017168444A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- mixture
- acid
- solvent
- Prior art date
Links
- 0 *N(CC[C@@]1(CCCC2)O)C(Cc(cc3)ccc3O*)[C@@]12O Chemical compound *N(CC[C@@]1(CCCC2)O)C(Cc(cc3)ccc3O*)[C@@]12O 0.000 description 5
- IOXDLRSZYPCACE-UHFFFAOYSA-N COc1cc(C(CC23CNC4C2)(CCCC2)C42O)c3cc1 Chemical compound COc1cc(C(CC23CNC4C2)(CCCC2)C42O)c3cc1 IOXDLRSZYPCACE-UHFFFAOYSA-N 0.000 description 1
- AXSUBGWSFRMJJD-UHFFFAOYSA-N COc1cc(C2(CC34CNC5C3)C5(C3)[O](C)C3CC2)c4cc1 Chemical compound COc1cc(C2(CC34CNC5C3)C5(C3)[O](C)C3CC2)c4cc1 AXSUBGWSFRMJJD-UHFFFAOYSA-N 0.000 description 1
- KDQUELJYUXWGKL-UHFFFAOYSA-N OC1(CCCCC1)C(C1)N(CC2CCC2)CC1(CC1)c(cc2)c1cc2O Chemical compound OC1(CCCCC1)C(C1)N(CC2CCC2)CC1(CC1)c(cc2)c1cc2O KDQUELJYUXWGKL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Definitions
- the present invention is in the field of chemistry, and more particularly the present invention relates to a preparation of Butorphanol tartrate in a very safe, economical, and user-friendly process using novel intermediates.
- Butorphanol tartrate (I) is chemically known as N-cyclobutylmethyl-3,14- dihydroxymorphinan tartrate, which is a morphinan-type synthetic opioid analgesic of phenanthrene series and is highly effective for the treatment of both chronic and acute pain.
- Parenterally administered Butorphanol tartrate is more potent than morphine and most other morphine analogs.
- Parenteral formulations of Butorphanol tartrateand its use for the relief of acute and chronic pain are first disclosed in theUS Patent 3,775,414 (hereinafter referred to as '414) and 3,819,635 (hereinafter referred to as '635).
- a parenteral formulation of Butorphanol tartrate is commercially available under the name Stadol ® from Bristol-Myers Laboratories, Inc.
- Stadol ® from Bristol-Myers Laboratories, Inc.
- the chemical structure of Butorphanol tartrate (I) is depicted below:
- the preparations of 14-hydroxymorphinan derivatives are schematically presented in scheme (1) and are disclosed in the aforesaid US patent '414.
- the scheme (1) consists of the condensation of 7-methoxy-3,4-dihydro-l(2H)-naphthalenone with 1,4 dibromobutane by means of sodium hydride(NaH) in benzene gives 3,4-dihydro-7- methoxy-2,2-tetramethylene-l(2H)-naphthalenone, which is treated with acetonitrile and n-butyllithium in tetrahydrofuran (THF)yieldingl-hydroxy-7-methoxy-l,2,3,4- tetrahydro-2,2-tetramethylene-l-naphthaleneacetonitrile.
- THF tetrahydrofuran
- This compound is reduced with lithium aluminium hydride (LAH or LiAlH 4 ) in THF to afford hydro-2,2-tetramethylene- 1-naphthol and isomerized to 4a-(2-aminoethyl)- 1 ,2,3, 4,4a,9-hexahydro-6-methoxy- phenantrene.
- LAH or LiAlH 4 lithium aluminium hydride
- This amine is cyclized by reaction with bromine in chloroform(CHCl 3 ) giving 3-methoxy-9a-bromonrhasybanan hydrobromide and isomerized with dehydrobromination by treatment with sodium bicarbonate(NaHC0 3 ) in N,N- Dimethylformamide (DMF) affording 3-methoxy-DELTA(8, 14)-morphinan.
- Butorphanol may also be prepared by another alternative synthetic procedure described in the said US patent '635 by Bristol-MyersCompany.
- the procedure of said US patent '635 schematically presented in scheme (2) is depicted below:
- US patent '635 discloses the process for the preparation of Butorphanol involving the use of 7-methoxy-3,4-dihydro-l(2H)- naphthalenone compound as starting material which undergoes series of reaction steps to form Butorphanol.
- the process of the present invention involves the use of 4- methoxyphenylacetic acid and 2-( 1 -cyclohexenyl)ethylamine to finally forms Butorphanol.
- the starting material used in the process disclosed in US patent '635 is expensive, whereas the starting material used in the present invention are economicallyand commercially available.
- the said US patents '414 and '635 discloses mixtures of isomers at all stages and involves costly last-step resolution, which is a major disadvantage.
- the present invention overcome this disadvantage by providing an economic method with increased yield and purity.
- An object of the present invention is to provide an improved process for the preparation of a compound of formula (I), which is simple, economical, user- friendly and commercially viable.
- Another object of the present invention is to provide a process for the preparation of a compound of formula (I), which would be easy to implement on commercial scale, and to avoids the use of expensive reagent(s) and hazardous organic solvent(s), which makes the present invention eco-friendly as well.
- Yet another object of the present invention is to provide a process for the preparation of a compound of formula (I) in a greater yield with higher chemical& chiral purity.
- Yet another object of the present invention is to provide a process for the preparation of a compound of formula (IVc), wherein the byproduct formed of formula (IVd) during the reaction can be reusable and thereby recyclable, which makes the process industrially more suitable.
- Yet another object of the present invention is to provide novel compound of Formula (V), Formula (Via) and Formula (VIb) of the N-substituted-isoquinoline derivatives.
- Still another object of the present invention is to provide novel process for preparation of Formula (V), Formula (Via) and Formula (VIb) of the N-substituted-isoquinoline derivatives.
- the present invention provides an improved process for the preparation of Butorphanol tartrate of formula I),
- the present invention provides an improved process for the preparation of Butorphanol tartrate of formula (I) via novel synthetic approach usin novel intermediates.
- the compound of formula (IV) of step (a) is obtained by following the various steps such as condensation, cyclization and reduction in in-situ manner via suitable conditions described herein.
- the compound of formula (II) and (III) undergo for the condensation using an organic solvent under reflux conditions.
- the condensed intermediate is cyclized using an acid and an organic solvent, further cyclized intermediate is undergone for reduction using suitable reducing agent in presence of a suitable base.
- the said solvent used in step (a) and step (b) may be preferably selected from the group consisting of water,xylene, benzene, toluene, ethylbenzene, cyclohexane and the like or mixture of solvents thereof; more preferably xylene of step (a) and toluene and water (b).
- the said acid used in step (a) is phosphorus oxychloride or any other suitable acid.
- step (a) wherein the said reducing agent used in step (a) may be preferably selected from the group consisting of sodium borohydride, lithium borohydride, lithium aluminium hydride and the like or mixture thereof; more preferably sodium borohydride.
- step (a) wherein the said reducing agent used in step (a) may be selected as mixture of sodium borohydride with iodine and the like.
- step (a), step (c) and step (f) may be preferably selected from organic base or an inorganic base.
- the said organic base is selected from the group consisting of pyridine ormono, di and tri alkyl amine, which are further selected from the group consisting of methyl amine, triethyl amine, diisopropylethyl amineand the like.
- the said inorganic base is selected from the group consisting of potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, alkali or alkaline earth metal hydroxides such as sodium hydroxide, potassium hydroxide and the like.
- the preferred base in step (a) is sodium hydroxide
- in step (c) is triethyl amine
- step (f) is sodium bicarbonate.
- step (b) wherein the said resolving agent used in step (b) isS (+) mandelic acid or any suitable resolving agent.
- step (c), step (d), step (e)and step (h) is chlorinated solvent, which may be preferably selected from thegroup consisting of ethylene dichloride, chloroform, dichloromethane and the like or mixture thereof; more preferably in step (c), step (d), step (e)and step (h) is dichloromethane.
- the said peroxy acid used in step (d) is OT-chloroperbenzoic acid or any suitable peroxy acid.
- the said acid used in step (e) is sulfuric acid (H 2 SO 4 ) or any suitable acid.
- the said solvent used in step (e) may be preferably selected from the group consisting of water,ketonic solvents such as acetone, methyl ethyl ketone (MEK) and methyl isobutyl ketone (MIBK)and the like or mixture thereof; more preferably is acetone and water.
- ketonic solvents such as acetone, methyl ethyl ketone (MEK) and methyl isobutyl ketone (MIBK)and the like or mixture thereof; more preferably is acetone and water.
- step (f) wherein the said solvent used in step (f) is preferably selected from polar aprotic solvent or mixture thereof; more preferably isN, N-dimethylformamide .
- step (g) ispolyphosphoric acid.
- step (g) wherein the said solvent used in step (g)is tetrahydrofuran or any othersuitable solvent, which is in the form of borane- tetrahydrofuran or any other borane-solvent complex.
- the said demethylating agent in step (h) may be preferably selected from the group consisting ofsodium dithionate, potassium dithionate, barium dithionate, boron tribromide (BBr 3 ),phosphorus tribromide (PBr 3 ) andthe likeor mixture thereof; more preferably is boron tribromide.
- the said solvent used in step (i) may be preferably selected from the group consisting of methanol, ethanol, isopropanol, n- propanol, n-butanol, acetone, methyl ethyl ketone and methyl isobutyl ketone, and the like or mixture thereof; more preferably is methanol and acetone.
- step (a) and (b) wherein all the steps of instant invention may be preferably carried out at 0°C to ambient temperature or to reflux temperature. In another embodiment of the present invention, wherein all the steps or some of the steps may be performed in in-situ manner. More particularly the step (a) and (b), the step (c), (d) and (e) and step (g) and (h) are performed in-situ manner.
- reaction mixture allowed to cool to 25 °C to 30°C and extracted with water (1800mL) and aqueous solution was basified with 50% caustic lye solution to pH 5.0 to 5.5.
- a solution of sodium borohydride (33.5g, 0.886 moles) in water (67.5mL) and 50% caustic lye solution (0.9mL) was added in 2 to 3 h and stirred at 25 to 30°C for 5.0 h.
- Toluene (900mL) was added and pH was maintained to 8.5 to 9.0 using 50% caustic lye solution ( ⁇ 165mL).
- reaction mixture was allowed to cool to 25 °C to 30°C and extracted with water (1200 mL) and aqueous solution was washed with toluene (400 mL) and basified with 50% caustic lye solution to pH 5.0 to 5.5.
- a solution of sodium borohydride (31.19g, 0.8244 moles) in water (61mL) and 50% caustic lye solution (0.8mL) was added in 2 to 3 h and stirred at 25 °C to 30°C for 5.0 h.
- Toluene (600mL) was added and pH was maintained to 7.5 to 8.5 using 50% caustic lye solution.
- the aqueous layer was separated from reaction mixture, extracted with toluene (400mL) combined with main organic layer and washed with water (800mL) and brine (400mL).
- water 680mL
- S (+)-mandelic acid 158 g, 1.0382 moles
- the reaction mixture allowed to cool gradually to 25°C to 30°C, filtered, washed with toluene (200mL) and suck dried.
- racemiccompound of formula (IV) 616.0g, 2.393 moles
- S (+)-mandelic acid 236.7g, 1.555 moles
- the reaction mixture was allowed to cool to 25°C to 30°C, filtered, washed with toluene (800mL) and suck dried.
- water (1200mL) and toluene (925mL) was added, pH was maintained to 12.0 to 13.5 using 50% caustic lye solution.
- the reaction mixture was allowed to cool to 25°C to 35°C and extracted with water (1.8L) and aqueous solution was basified with 50% caustic lye solution to pH 5.0 to 5.5.
- a solution of sodium borohydride (33.5g, 0.886 moles) in water (67.5mL) and 50% caustic lye solution (0.9mL) was added in 2 to 3 h and stirred at 25 °C to 30°C for 5.0 h.
- Toluene (900mL) was added and pH was maintained to 8.5 to 9.0 using 50% caustic lye solution ( ⁇ 165mL).
- the aqueous layer was separated from reaction mixture, extracted with toluene (1200mL), combined with main organic layer and washed with water (1200mL).
- water (1020mL) S (+) Mandelic acid was added and heated to 75°C to 80°C for 1.0 h.
- the reaction mixture was allowed to cool to 25 °C to 30°C, filtered, washed with toluene (800mL) and suck dried.
- To the wet cake water (1200mL) and toluene (925mL) was added and the pH was maintained to 12.0 to 13.5 using 50% caustic lye solution.
- meta-chloroperoxybenzoic acid (119. lg, 0.690 moles) was added lot wise at 0°C to 5°C for 1.0 h.
- the reaction mixture was allowed to warm to 25 °C to 30°C and stirred for 2.0 h.
- the resulting solid was filtered and filtrate was washed with 1M sodium bisulfite, saturated sodium bicarbonate till effervescences stopped.
- the organic layer further was washed with water, brine and evaporated under reduced pressure to yield light brown colour semisolid compound (150.0g, 95.7% yield).
- reaction mixture was cooled to 0°C to 5°C, water (1550mL) was charged and pH was adjusted to 12.0 to 12.5 using 50% caustic lye solution ( ⁇ 115mL) below 20°C.
- the reaction mixture was allowed to warm to 40°C to 45 °C, stirred for 1.0 h, filtered, washed with water (775mL) and dried to yield (95.0g, 78.9% yield) as anoff-white solid with HPLC purity 78.11% (Vllb, ira/w-isomer) and 19.89% (Vila, cis- isomer).
- themeta-chloroperoxybenzoic acid 140.11 g, 0.6150moles
- the solid was filtered and filtrate was washed with 1M sodium bisulfite solution (630mL X 3), with 5% sodium bicarbonate solution (630mL X 3), water (630mL) and with brine solution (420mL).
- the organic layer was separated and evaporated under reduced pressure to yield light brown colour semisolid compound.
- acetone 567mL
- Reaction mixture was filtered, washed with water (125mL) and dried to (26.0g) yield crude compound.
- the crude compound was purified by stirring with IPA (50mL) at 5°C to 10°C for 1.0 h. After 1.0 h reaction mixture was filtered, washed with cold IPA (25mL) and dried to yield (22.6g, 73% yield) as a off white solid with HPLC purity 89.86% of formula (VHIb, trans-homer) and 9.29 % of formula (Villa, cis- isomer).
- reaction mixture was cooled to 5°C to 10°C and water (75mL) was added dropwise and adjusted to pH 8.0 to 9.0 using liquid ammonia (115mL).
- the reaction mixture was extracted with ethyl acetate (50mL x 3) and combined organic layer washed with water (75mL) and brine (lOmL) solution.
- the organic layer evaporated under reduced pressure to yield (3.66g, 77% yield) as light brown oily compound of formula (IX) with HPLC purity 71.14%.
- reaction mixture was further cooled to 0°C to 5°C, water (22.5mL) was added and pH was adjusted to 8.0 to 9.0 using liquid ammonia (9.0mL).
- the reaction mixture was extracted with dichloromethane (45.0mL x 2) and combined organic layer washed with water (45.0mL) and brine solution (9.0mL).
- the organic layer was evaporated under reduced pressure to yield (4.67g) crude compound as a light brown solid.
- the crude compound was stirred in methanol (9.0mL) at 0°C to 5°C, filtered and dried to yield (2.5 lg, 59% yield) as anoff-white solid of formula (X) with HPLC purity 98.38%.
- the reaction mixture was cooled to 10°C to 15°C and water (4.5 L) was added drop wise.
- dichloromethane (4.5 L) was added and pH was adjusted to 7.0 to 8.0 using 25% liquid ammonia (6.9 L).
- the reaction mixture was extracted with dichloromethane (2.250 L) and combined organic layer washed with water (4.5 L), brine (1.35 L) solution.
- the organic layer was cooled to 0°C to 5°C and 1M BBr 3 solution in dichloromethane (2.5 Lit) was added drop wise at 0°C to 5°C.
- reaction mixture allowed to warm to 25°C to 30°C, stirred for 3.0 h and further cooled to 0°C to 5°C and water (4.5 L) was added and pH was adjusted to 8.0 to 9.0 using liquid ammonia (450mL).
- the organic layer was separatedand aqueous layer was extracted with dichloromethane (2.25 L), combined organic layer washed with water (4.5 L X 2) and evaporated under reduced pressure to yield brown coloured crude compound.
- ExamplelO.O Morphinan-3.14-diol.l7-(cvclobutylmethvn-.(-)-.rS-(R :1: .R :1: )l-2.3- dihydroxybutanedioate salt (I)
- the organic layer was separated, aqueous layer extracted with methyl tert-butyl ether (400mL) and combined organic layer dried over sodium sulphate and cooled to 5°C to 10°C and a solution of potassium hydroxide (116.84g, 2.0820 moles) in methanol (300mL) was added slowly.
- the reaction mixture was warmed to 20°C to 25°C and stirred for 2 h and water (300mL) was added and further cooled to 5°C to 10°C.
- the solution of sodium borohydride (25.86g, 0.6830 moles) and NaOH (8g, 0.1990 moles) in water (200mL) was added slowly and reaction mixture was warmed to 20°C to 25°C and stirred for 2 h.
- the process of the present invention uses a solvent and intermediate(s) which can be recycled and reused and thus makes the process more economical and industrially & commercially viable.
- the process of the present invention is a simple process, which avoids more number of operations, thus resulting in shortening of reaction time and lowering of labour.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017242268A AU2017242268A1 (en) | 2016-03-29 | 2017-03-27 | An improved process for the preparation of butorphanol tartrate |
US16/089,505 US10544101B2 (en) | 2016-03-29 | 2017-03-27 | Process for the preparation of butorphanol tartrate |
MX2018011877A MX2018011877A (en) | 2016-03-29 | 2017-03-27 | An improved process for the preparation of butorphanol tartrate. |
EP17773452.2A EP3436425B1 (en) | 2016-03-29 | 2017-03-27 | An improved process for the preparation of butorphanol tartrate |
JP2018550826A JP6980687B2 (en) | 2016-03-29 | 2017-03-27 | Improved method for the production of butorphanol tartrate |
CA3019491A CA3019491A1 (en) | 2016-03-29 | 2017-03-27 | An improved process for the preparation of butorphanol tartrate |
CN201780021769.3A CN109071414B (en) | 2016-03-29 | 2017-03-27 | Improved process for the preparation of butorphanol tartrate |
KR1020187030746A KR20180129854A (en) | 2016-03-29 | 2017-03-27 | Improved Preparation of Butorphanol Tartrate |
IL261986A IL261986B (en) | 2016-03-29 | 2018-09-27 | An improved process for the preparation of butorphanol tartrate |
PH12018550165A PH12018550165A1 (en) | 2016-03-29 | 2018-09-27 | An improved process for the preparation of butorphanol tartrate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201621010777 | 2016-03-29 | ||
IN201621010777 | 2016-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017168444A1 true WO2017168444A1 (en) | 2017-10-05 |
Family
ID=59963601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2017/050112 WO2017168444A1 (en) | 2016-03-29 | 2017-03-27 | An improved process for the preparation of butorphanol tartrate |
Country Status (12)
Country | Link |
---|---|
US (1) | US10544101B2 (en) |
EP (1) | EP3436425B1 (en) |
JP (1) | JP6980687B2 (en) |
KR (1) | KR20180129854A (en) |
CN (1) | CN109071414B (en) |
AU (1) | AU2017242268A1 (en) |
CA (1) | CA3019491A1 (en) |
CL (1) | CL2018002756A1 (en) |
IL (1) | IL261986B (en) |
MX (1) | MX2018011877A (en) |
PH (1) | PH12018550165A1 (en) |
WO (1) | WO2017168444A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109694348A (en) * | 2018-11-12 | 2019-04-30 | 江苏宝众宝达药业有限公司 | A kind of dextromethorphan intermediate splits the racemization recovery method of recovered material in mother liquor |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112142668B (en) * | 2019-06-28 | 2022-06-21 | 苏州盛迪亚生物医药有限公司 | Preparation method of butorphanol tartrate and intermediate thereof |
CN112159356A (en) * | 2020-10-09 | 2021-01-01 | 赤峰艾克制药科技股份有限公司 | Racemization recovery method of dextromethorphan hydrobromide intermediate byproduct |
CN114685370A (en) * | 2020-12-25 | 2022-07-01 | 成都苑东生物制药股份有限公司 | Butorphanol tartrate crystal form I and preparation method and application thereof |
CN116818928B (en) * | 2023-04-28 | 2024-04-19 | 杭州沐源生物医药科技有限公司 | Separation detection method for impurities in butorphanol tartrate injection |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH301668A (en) * | 1949-07-29 | 1954-09-15 | Hoffmann La Roche | Process for the preparation of a morphine derivative. |
US3775414A (en) * | 1972-05-10 | 1973-11-27 | Bristol Myers Co | Process for the preparation of 14-hydroxymorphinan derivatives |
US3980641A (en) * | 1975-07-31 | 1976-09-14 | Bristol-Myers Company | Process for the preparation of 14-hydroxymorphinans |
US4139534A (en) * | 1977-02-17 | 1979-02-13 | Bristol-Myers Company | Process for the preparation of 14-hydroxymorphinan derivatives |
US4058531A (en) * | 1976-03-23 | 1977-11-15 | Bristol-Myers Company | Process for the preparation of 14-hydroxymorphinan derivatives |
CN102977021A (en) * | 2012-11-29 | 2013-03-20 | 威海迪之雅医药化工开发有限公司 | Preparation method of dextromethorphan hydrobromide |
-
2017
- 2017-03-27 CA CA3019491A patent/CA3019491A1/en active Pending
- 2017-03-27 US US16/089,505 patent/US10544101B2/en active Active
- 2017-03-27 MX MX2018011877A patent/MX2018011877A/en unknown
- 2017-03-27 CN CN201780021769.3A patent/CN109071414B/en active Active
- 2017-03-27 EP EP17773452.2A patent/EP3436425B1/en active Active
- 2017-03-27 KR KR1020187030746A patent/KR20180129854A/en unknown
- 2017-03-27 WO PCT/IN2017/050112 patent/WO2017168444A1/en active Application Filing
- 2017-03-27 AU AU2017242268A patent/AU2017242268A1/en not_active Abandoned
- 2017-03-27 JP JP2018550826A patent/JP6980687B2/en active Active
-
2018
- 2018-09-27 PH PH12018550165A patent/PH12018550165A1/en unknown
- 2018-09-27 CL CL2018002756A patent/CL2018002756A1/en unknown
- 2018-09-27 IL IL261986A patent/IL261986B/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
FREDERICK C. COPP ET AL.: "A Novel Ring Closure leading to 3,9-Dihydroxyaporphines (3,9-Dihydroxy-4H-di benzo [ de,g] quinolines", JOURNAL OF THE CHEMICAL SOCIETY,, vol. 11, 1 January 1985 (1985-01-01), pages 2455 - 2462, XP055430556 * |
R. DANIEL LITTLE ET AL.: "A Stereo selective Total Synthesis of 14-Hydroxyrnorphinans, Grewe Approach", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 100, no. 14, 5 July 1978 (1978-07-05), pages 4609 - 10, XP055430553 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109694348A (en) * | 2018-11-12 | 2019-04-30 | 江苏宝众宝达药业有限公司 | A kind of dextromethorphan intermediate splits the racemization recovery method of recovered material in mother liquor |
CN109694348B (en) * | 2018-11-12 | 2022-07-05 | 江苏宝众宝达药业股份有限公司 | Racemization recovery method for recovering materials from resolution mother liquor of dextromethorphan intermediate |
Also Published As
Publication number | Publication date |
---|---|
CN109071414A (en) | 2018-12-21 |
CN109071414B (en) | 2021-11-05 |
AU2017242268A1 (en) | 2018-10-25 |
CA3019491A1 (en) | 2017-10-05 |
EP3436425B1 (en) | 2021-01-06 |
KR20180129854A (en) | 2018-12-05 |
CL2018002756A1 (en) | 2019-02-01 |
EP3436425A1 (en) | 2019-02-06 |
IL261986A (en) | 2018-10-31 |
US10544101B2 (en) | 2020-01-28 |
JP6980687B2 (en) | 2021-12-15 |
JP2019511508A (en) | 2019-04-25 |
IL261986B (en) | 2021-03-25 |
EP3436425A4 (en) | 2019-09-04 |
US20190112273A1 (en) | 2019-04-18 |
MX2018011877A (en) | 2019-03-06 |
PH12018550165A1 (en) | 2019-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3436425B1 (en) | An improved process for the preparation of butorphanol tartrate | |
US11453670B2 (en) | Substituted heterocycle fused gamma-carbolines synthesis | |
KR101981840B1 (en) | Substituted heterocycle fused gamma-carbolines synthesis | |
WO2017016960A1 (en) | Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues | |
US8877931B2 (en) | Process and intermediates for preparing integrase inhibitors | |
SK15952000A3 (en) | Aryl fused azapolycyclic compound, the use thereof and pharmaceutical compositions based thereon | |
Ronson et al. | Synthetic approaches to pallimamine and analogues using direct imine acylation | |
KR20210104833A (en) | Substituted Heterocycle Fusion Gamma-Carboline Synthesis | |
EP2824103A1 (en) | An improved process for the preparation of Rupatadine Fumarate | |
EP2867210A1 (en) | A process for the preparation of solifenacin or a salt thereof | |
WO2016079109A1 (en) | Process for the preparation of perhydroquinoxaline derivatives | |
EP2628728A1 (en) | Process for the optical resolution of 1-(4-methoxybenzyl)-octahydro-isoquinoline | |
Chen et al. | Synthetic studies on (+)-biotin, part 15: A chiral squaramide-mediated enantioselective alcoholysis approach toward the total synthesis of (+)-biotin | |
Couturier et al. | Efficient synthesis of the κ-opioid receptor agonist CJ-15,161: four stereospecific inversions at a single aziridinium stereogenic center | |
KR20210104834A (en) | Substituted Heterocycle Fusion Gamma-Carboline Synthesis | |
JP2014532059A (en) | 5- (2-{[6- (2,2-difluoro-2-phenylethoxy) hexyl] amino} -1 (R) -hydroxyethyl) -8-hydroxyquinoline-2 (1H)-through a novel intermediate ON manufacturing method | |
GB1568976A (en) | Cis-4-phenyl-isoquinolines | |
WO2023122754A1 (en) | Processes and intermediates for preparing gb13, gb22 and himgaline | |
CN113845478A (en) | Intermediate, preparation method and application thereof | |
KR20240024937A (en) | Method for producing CYP11A1 inhibitors and intermediates thereof | |
WO2022127321A1 (en) | Novel intermediate, preparation method for same, and applications thereof | |
KR20130077458A (en) | Method of preparing benzodiazepine derivatives | |
CN114133323A (en) | Preparation method of polysubstituted phenylacetic acid derivative | |
CZ20003972A3 (en) | Aryl fused azapolycyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018550826 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/011877 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 3019491 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187030746 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017242268 Country of ref document: AU Date of ref document: 20170327 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017773452 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017773452 Country of ref document: EP Effective date: 20181029 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17773452 Country of ref document: EP Kind code of ref document: A1 |